gliclazide has been researched along with s-nitro-n-acetylpenicillamine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahluwalia, A; Chauhan, S; Scotland, RS; Vallance, PJ | 1 |
1 other study(ies) available for gliclazide and s-nitro-n-acetylpenicillamine
| Article | Year |
|---|---|
An endothelium-derived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Apamin; Barium; Biological Factors; Calcium; Charybdotoxin; Endothelium, Vascular; Enzyme Inhibitors; Female; Genotype; Glycyrrhetinic Acid; In Vitro Techniques; Indomethacin; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Knockout; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Penicillamine; Potassium Channel Blockers; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2001 |